Previous 10 | Next 10 |
home / stock / zldpf / zldpf news
Company announcement - No. 20 / 2023 Zealand Pharma Announces Financial Results for the First Quarter of 2023 Positive topline data from obesity portfolio On track for two regulatory submissions targeting rare diseases Strengthened balance sheet with DKK 1.5 billio...
2023-05-10 05:54:01 ET Boehringer Ingelheim and Zealand Pharma A/S ( OTCPK:ZLDPF ) said patients receiving their drug BI 456906 achieved up to 14.9% weight loss after 46 weeks, using the planned maintenance dose in a phase 2 trial. The phase 2 trial evaluating different doses of the...
Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight Phase II dose-finding trial met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim’s cardio-...
Press Release– No. 3 / 2023 Zealand Pharma Hosts Conference Call on May 11 at 2pm CET (8am ET) to Present First Quarter 2023 Results Copenhagen, Denmark, May 4, 2023 – a Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery...
Press release – No. 2 / 2023 Zealand Pharma to Participate in 22nd Annual Needham Virtual Healthcare Conference Copenhagen, Denmark, April 12, 2023 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the dis...
Company announcement – No. 11 / 2023 Zealand Pharma announces completion of a directed issue and private placement of 6,578,948 million new ordinary shares raising gross proceeds of DKK 1.5 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO TH...
Company announcement – No. 10 / 2023 Zealand Pharma announces directed issue and private placement of approximately 6.5 million new shares NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, ...
Company announcement – No. 7 / 2023 Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396 Dose-dependent body weight reductions of up to a mean of 4.2% from baseline (4.8% placebo corrected) following a single dose of ZP8396 In devel...
2023-03-12 13:00:16 ET New weight loss therapies could cause a significant strain on Medicare due to cost implications, a group of health experts warned last week in an article published in The New England Journal of Medicine on Saturday amid legislative efforts to gain coverage. ...
Company announcement – No. 3 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, March 9 , 202 3 – Zealand Pharma A/S (“Zealand”) (...
News, Short Squeeze, Breakout and More Instantly...
Zealand Pharma A/S Ord Company Name:
ZLDPF Stock Symbol:
OTCMKTS Market:
Zealand Pharma A/S Ord Website:
Company announcement – No. 35 / 2024 Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE U...
Company announcement – No. 34 / 2024 Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO T...
Company announcement – No. 33 / 2024 Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CAN...